peginterferon alfa-2b + nucleoside analogs

This combination therapy regimen, being studied by Qilu Hospital of Shandong University, consists of peginterferon alfa-2b and nucleoside analogs (NAs) for the treatment of chronic hepatitis B (CHB). Peginterferon alfa-2b is a pegylated biologic that functions as an immunomodulator and antiviral agent by binding to Type I interferon receptors (IFNAR1/2), while nucleoside analogs such as entecavir or tenofovir are small molecules that directly inhibit the HBV DNA polymerase. The combination aims to achieve a functional cure, characterized by sustained HBsAg clearance and undetectable HBV DNA, which is difficult to achieve with NA monotherapy alone. The specific clinical research at Qilu Hospital involves developing logistic regression models to predict durable functional cure in patients receiving this combination therapy based on baseline clinical indicators.

Brand names

PegIntronBaracludeVireadVemlidy

Other names

peginferferon-α + nucleoside analogs-Qilu Hospital of Shandong University-chronic hepatitis BPeg-IFNα + NAsPeginterferon-α + Nucleoside analogsPegylated Interferon Alpha-2b Based Therapy